Kian Fan Chung (London, United Kingdom), Huib A.M. Kerstjens (Groningen, Netherlands)
LATE-BREAKING ABSTRACT: Single-dose safety, tolerability, PD & PK of AZD8999, a bi-functional muscarinic antagonist/β2-agonist (MABA), in patients with COPD
Dave Singh (Manchester, United Kingdom), Dave Singh, Tim Mant, Helena Pujol, Èric Massana, Meritxell Falques, Marisa Gonzalez, Carol Astbury
|   |
Central role of AC6 in β2 agonist induced relaxation of human airway smooth muscle
Eric Dubuis (London, United Kingdom), Eric Dubuis, Catherine Wrench, Bilel Dekkak, Fisnik Shala, Yasin Shaifta, Jeremy Ward, Julia Gorelik, Maria Belvisi, Mark Birrell
| |
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery
Fabrizio Facchinetti (Parma, Italy), Nadia Moretto, Carmelida Capaldi, Elisabetta Armani, Mary Fitzgerald, Henry Finch, Craig Fox, Riccardo Patacchini, Maurizio Civelli, Gino Villetti, Fabrizio Facchinetti
| |
Inhibition of NOX2 oxidase activity ameliorates cigarette smoke-induced lung inflammation and wasting in mice
Ross Vlahos (Bundoora, Australia), Ivan Bernardo, Samantha Passey, Huei Jiunn Seow, Michelle Hansen, Steven Bozinovski, Ross Vlahos
| |
A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Janis Shute (Portsmouth Hampshire, United Kingdom), Janis Shute, Luigino Calzetta, Vittorio Cardaci, Stefania Di Toro, Clive Page, Mario Cazzola
| |
Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT)
Courtney Crim (Research Triangle Park, United States of America), Courtney Crim, Robert Brook, Julie Anderson, Sally Kilbride, Peter Calverley, Bartolome Celli, Fernando Martinez, Jørgen Vestbo, Julie Yates, David Newby
| |
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Amir Hakim (London, United Kingdom), Amir Hakim, Younis Khan, Ignacio Esteban, Anna Miller-Larsson, Peter Barnes, Omar Usmani
| |
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Dorothy Keininger (Basel, Switzerland), Dorothy Keininger, Jadwiga A. Wedzicha, Jørgen Vestbo, Tim Ayers, Angel FowlerTaylor, Chau Thach, Michael Larbig, Elaine Askin, Robert Fogel, Francesco Patalano, Donald Banerji
| |